Anniko® is the commercial brand name of Penpulimab Injection, a humanized anti-programmed death 1 (anti-PD-1) monoclonal antibody developed by CTTQ Sunccine Biotech. It binds to the PD-1 receptor on T cells, blocking its interaction with PD-L1/PD-L2, thereby restoring the immune…
Etesevimab is a humanized anti-SARS-CoV-2 neutralizing monoclonal antibody, co-developed by Eli Lilly and Company and Junshi Biosciences. It binds to the spike protein of SARS-CoV-2, blocking viral attachment and entry into host cells. It is authorized for use in combination…
Cejemly® is the commercial brand name of Sugemalimab Injection, a fully human anti-programmed death ligand 1 (anti-PD-L1) monoclonal antibody developed by CStone Pharmaceuticals and Pfizer. It binds to PD-L1 expressed on tumor cells and immune cells, blocking its interaction with…
Hansizhuang® is the commercial brand name of Serplulimab Injection, a recombinant humanized anti-programmed death 1 (anti-PD-1) monoclonal antibody developed by Henlius Biotech. It binds to the PD-1 receptor on T cells, blocking its interaction with PD-L1/PD-L2, thereby restoring the immune…
CARVYKTI® is the commercial brand name of ciltacabtagene autoleucel, a BCMA-directed genetically modified autologous T-cell immunotherapy developed by Janssen Biotech. It involves engineering the patient’s own T cells to express a chimeric antigen receptor (CAR) targeting B-cell maturation antigen (BCMA),…
Ensacove® is the commercial brand name of Ensartinib Hydrochloride Capsules, an orally active second-generation anaplastic lymphoma kinase (ALK) inhibitor developed by Betta Pharmaceuticals. It selectively inhibits ALK tyrosine kinase activity, blocking downstream signaling pathways to suppress the proliferation and survival…
SOLIRIS® is the commercial brand name of Eculizumab Injection, a humanized anti-C5 monoclonal antibody developed by Alexion Pharmaceuticals. It binds to complement protein C5, preventing its cleavage into C5a and C5b-9, thereby inhibiting terminal complement-mediated hemolysis and inflammation. Main IndicationsTreatment…
TEGLUTIK® is the commercial brand name of Riluzole Oral Suspension, an orally active antiglutamatergic agent. It inhibits glutamate release and blocks voltage-dependent sodium channels, exerting neuroprotective effects in amyotrophic lateral sclerosis (ALS). Main IndicationsTreatment of amyotrophic lateral sclerosis (ALS) in…
Taltz® is the commercial brand name of Ixekizumab Injection, a humanized anti-IL-17A monoclonal antibody developed by Eli Lilly. It selectively binds to interleukin 17A (IL-17A), inhibiting its interaction with the IL-17 receptor and blocking the inflammatory cascade in autoimmune diseases.…
Kisqali® is the commercial brand name of Ribociclib Tablets, an orally active CDK4/6 inhibitor developed by Novartis. It selectively inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), blocking the phosphorylation of retinoblastoma (Rb) protein to arrest the cell cycle in G1…